Collaboration Antigen definition

Collaboration Antigen means, with respect to each Program, the Antigen selected in accordance with Section 4.3; provided, that the Collaboration Antigen shall not be a Cue Reserved Antigen.
Sample 1Sample 2
Collaboration Antigen means any Antigen listed as a “Collaboration Antigen” on Exhibit B, as such Exhibit may be amended pursuant to Sections 2.2.1(j), 2.2.1(l), 2.2.2(c), 2.2.2(d), 2.3.1, 2.3.3, 2.6.4, 2.6.5, 4.15, 5.9, 5.11 and 16.8.3(a).
Sample 1Sample 2
Collaboration Antigen means the Initial Collaboration Antigen, the Second Collaboration Antigen and any other Antigen so designated pursuant to Sections 4.5.2 or 9.7.
Sample 1

Examples of Collaboration Antigen in a sentence

  • Upon the designation of an Antigen as a Prioritized Antigen or Collaboration Antigen, each Party shall, on written notice to the other Party, appoint a person (a “Project Leader”) to coordinate its activities prior to and under the Research Program for such Antigen.

  • Any Antibodies that were generated with respect to a Collaboration Antigen that show no binding affinity to such Collaboration Antigen shall be destroyed unless the Parties agree otherwise.

  • On an annual basis, or more often as the Parties deem appropriate, the JDC will prepare amendments to each then-current Research Plan for each Collaboration Antigen for approval of the JSC.

  • Each Party shall provide the other Party with updates on the current status of the research, development and commercialization of, with respect to AZ, the Licensed Products and, with respect to ABX, the ABX Products on a semiannual basis, provided that AZ shall have no obligation to provide such updates to ABX during any period in which ABX is performing activities under the Research Program or Development Program for the applicable Collaboration Antigen.

  • If the Parties reach mutual agreement on such financial terms within [Confidential treatment requested] after the receipt of such Antigen Notice, then such Advanced ABX Antigen shall be designated a Collaboration Antigen and Exhibit B shall be amended accordingly.

  • If any such ABX Diagnostic Antigen is designated as a Collaboration Antigen, then any such work performed by or on behalf of ABX prior to such designation shall be deemed to have been performed under the Research Program for such Collaboration Antigen and the provisions of Sections 11.1.1, 11.1.3, 11.1.4, 11.1.5 and 11.1.7 shall apply.

  • Upon receipt of such report, Information and materials, AZ shall have the right, for a period of [Confidential treatment requested], to designate such Antigen as a Collaboration Antigen under the terms set forth herein, regardless of the number of Collaboration Antigens that have been designated as of such date or whether the Antigen Designation Term has expired.

  • Unless otherwise agreed by AZ, such additional activities with respect to a Collaboration Antigen shall be performed by ABX (provided that, unless ABX otherwise consents in writing, all such additional work for all Collaboration Antigens does not exceed [Confidential treatment requested] additional FTEs in the aggregate for each year).

  • If the Advanced ABX Antigen is designated as a Collaboration Antigen, then all Information and inventions conceived or generated in connection with any work performed by or on behalf of ABX with respect to such Antigen prior to such designation that would have been Collaboration Technology if such work had been performed under a Research Program shall be Collaboration Technology and the provisions of Section 11.1.3 shall apply thereto.

  • If AZ elects to enter into a sublicense with a Third Party, AZ shall provide ABX with prompt written notice identifying the sublicensee and the Collaboration Antigen.


More Definitions of Collaboration Antigen

Collaboration Antigen means each of (i) a human papillomavirus (“HPV”) antigen and (ii) each other Antigen mutually selected by the Parties. For the avoidance of doubt, TCL is not a Collaboration Antigen.
Sample 1

Related to Collaboration Antigen

  • Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).

  • Collaboration Target means the Initial Collaboration Targets set forth on Exhibit F and any Additional Target or Substitute Target that is selected in accordance with Section 3.3 of this Agreement.

  • Lead Compound means any compound of lead other than galena which, when treated in the manner described below, yields to an aqueous solution of hydrochloric acid a quantity soluble lead compound exceeding, when calculated as lead monoxide, five percent of the dry weight of the portion taken analysis.

  • Development Candidate means a Compound that meets the Development Candidate Criteria for the initiation of a Development Program for the treatment of CF, and which is the subject of a notice from Vertex to CFFT that Vertex intends to commence formal pre-clinical development of the Compound in the Field pursuant to the provisions of Section 3.1 hereof.

  • Collaboration Product means any pharmaceutical product in finished form that contains a Collaboration Compound, either as the sole active ingredient or in combination with one or more other active ingredients, and all present and future formulations, dosages and dosage forms thereof.

  • Licensed Compound means a TAK-385 Licensed Compound or a TAK-448 Licensed Compound.

  • Product Candidate means each biological and drug candidate, compound or other device or product being developed, labeled, manufactured, marketed, sold and/or distributed by the Company or a Company Subsidiary, or regarding which the Company or a Company has rights, and including any such biological and drug candidate, compound or product that has received Marketing Approval.

  • Licensed Compounds means: (a) Research Program Active Compounds; (b) Novartis Active Compounds; (c) salts, hydrates, solvates, esters, metabolites, intermediates, stereoisomers and polymorphs of Research Program Active Compounds or Novartis Active Compounds; and (d) prodrugs of Research Program Active Compounds or Novartis Active Compounds (any of the foregoing, a “Licensed Compound”).

  • Collaboration Know-How means all Know-How conceived, discovered, developed or otherwise made by or on behalf of a particular Party or any of its Affiliates or permitted subcontractors of any of the foregoing (solely or jointly by or on behalf of a particular Party or any of its Affiliates or permitted subcontractors of any of the foregoing) in the course of [***].

  • Antibody means a molecule or a gene encoding such a molecule comprising or containing one or more immunoglobulin variable domains or parts of such domains or any existing or future fragments, variants, modifications, or derivatives thereof, but excluding single variable domains (heavy or light) of such antibodies.

  • Antigen means a substance recognized by the body as being foreign; it results in the production of specific antibodies directed against it.

  • Collaboration IP means Collaboration Know-How and Collaboration Patents.

  • Collaboration Patent Rights means Patent Rights claiming Collaboration Know-How.

  • Research Program has the meaning set forth in Section 3.1.

  • Collaboration Term has the meaning set forth in Section 2.2.

  • Research Program Term means the duration of the Research Program as it may be extended or terminated as described more fully in Section 2.10 and Article 8.

  • Collaboration Patents means any and all Patents that claim or cover any of the Collaboration Know-How.

  • Collaboration has the meaning set forth in Section 2.1.

  • Research Plan shall have the meaning set forth in Section 2.1.

  • Back-Up Compound means, with reference to any particular Development Candidate or Drug Product Candidate, a Compound which (a) has the same principal mode of action (i.e., Potentiator or Corrector) as that Development Candidate or Drug Product Candidate; and (b) was among the group of Compounds, identified by VERTEX as potential additional lead molecules having the same principal mode of action, from which the Development Candidate was selected.

  • Collaborating physician means the physician who,

  • Collaboration Technology means all Collaboration Patents and Collaboration Know-How.

  • Collaborator An individual who is not under the direct supervision of the PI (e.g., not a member of the PI’s laboratory) who assists with the PI’s research project involving controlled-access data subject to the NIH GDS Policy. Internal collaborators are employees of the Requester and work at the same location/campus as the PI. External collaborators are not employees of the Requester and/or do not work at the same location as the PI, and consequently must be independently approved to access controlled-access data subject to the NIH GDS Policy.

  • Commercialization or “Commercialize” means any and all activities undertaken at any time for a particular Licensed Product and that relate to the manufacturing, marketing, promoting, distributing, importing or exporting for sale, offering for sale, and selling of the Licensed Product, and interacting with Regulatory Authorities regarding the foregoing.

  • Massive Multiauthor Collaboration Site (or “MMC Site”) means any World Wide Web server that publishes copyrightable works and also provides prominent facilities for anybody to edit those works. A public wiki that anybody can edit is an example of such a server. A “Massive Multiauthor Collaboration” (or “MMC”) contained in the site means any set of copyrightable works thus published on the MMC site.

  • Development Program means the implementation of the development plan.